Medicines patent pool receives first licence for HIV drugs from major pharmaceutical company

Gilead Sciences has become the first pharmaceutical company to set up a licensing agreement with the recently-established Medicines Patent Pool (MPP), in a move aimed toward increasing access in developing countries to drugs that treat HIV and Hepatitis B. The landmark deal was announced yesterday, 12 July.